Purdue uHT-DESI-MS Platform Integrates Synthesis and Screening to Cut Early Cancer Drug Discovery to Hours

The PNAS study describes an ultrahigh-throughput DESI-MS system that performs on-surface synthesis of small-molecule libraries, direct biological incubation with purified cancer enzymes or cells, and immediate mass-based readout of binding or activity without purification steps. In one demonstrated case the platform disproved target engagement for a compound pursued for several years by conventional methods, redirecting effort within a single day. This addresses the historical lag between automated biology and manual chemistry noted by lead author Nicolás Morato.

Contextually the advance aligns with parallel efforts such as the 2023 Nature Reviews Drug Discovery analysis of acoustic liquid handling and the 2024 Science paper on AlphaFold-multimer-guided covalent library design; both highlight that hit rates remain limited by the speed of orthogonal validation rather than virtual enumeration. Purdue's integrated physical workflow supplies the missing experimental throughput layer.

Next steps include coupling the platform to patient-derived organoid libraries and scaling reaction diversity beyond the current DESI-compatible chemistries. Regulatory agencies will require standardized data packages from such accelerated workflows before they influence IND submissions.

Remaining questions center on false-negative rates for membrane targets and the generalizability of the four-hour cycle to PROTAC and molecular glue modalities.